Merck KGaA fined in Canada over vitamin price-fixing

6 April 2000

In Canada, the federal court has fined Merck KGaA C$1 million ($689,900)for its role in a price-fixing cartel, that ran from 1991 to 1995, artificially inflating prices in the C$700 million-a-year bulk vitamin C market (Marketletters passim). In addition, the court has issued a 10-year prohibition order, during which any attempt by the company to engage in anticompetitive practices will carry significantly stronger penalties, according to the Ottawa Citizen newspaper.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight